Navigation Links
PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
Date:12/8/2009

ANNAPOLIS, Md., Dec. 8 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it will hold a conference call at 9:00 a.m. Eastern Time, on Wednesday, December 9, 2009 to provide an update on its recombinant protective antigen (rPA) anthrax vaccine program. The dial-in number for U.S. callers is 866-383-8108 and for international callers is 617-597-5343. The participant passcode is 50815141.

A replay of the conference call will be available beginning at approximately 1:00 p.m. Eastern Time on December 9, 2009 until approximately 11:59 p.m. Eastern Time January 9, 2010. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 67021476.

The webcast of the conference call will be available until January 9, 2010 and can be accessed from the company's website at http://www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim®-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) -- a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

SOURCE PharmAthene, Inc.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
2. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
3. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
4. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
5. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
6. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
7. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
8. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
9. PharmAthene Reports First Quarter 2009 Financial and Operational Results
10. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
11. PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... Michael Fitzmaurice recently became double board-certified in surgery and surgery of the hand ... Dr. Fitzmaurice is no stranger to going above and beyond in his pursuit ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding ... has granted the company’s orphan drug designation request covering BHV-4157 for the treatment ... by the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder ...
(Date:5/23/2016)... ... ... need for blood donations in South Texas and across the nation is growing. , But ... blood donations are on the decline. In fact, donations across the country are at their ... Texas in the last four years alone. , There is no substitute for blood. , ...
Breaking Biology Technology:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):